Considering the importance of imatinib, an ABL tyrosine kinase inhibitor used in the treatment of BCR/ABL-positive CML, inhibitors against other tyrosine kinases are likely to become increasingly important for the treatment of AML [19,23]. Here, ABL1 is linked to acute myeloid leukemia.